Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation
Authors:
Open Access
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 111, 452-459
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptorsScientific Reports, 2013
- Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular diseaseJournal of Allergy and Clinical Immunology, 2012
- Leukotrienes as Modifiers of Preclinical Atherosclerosis?The Scientific World Journal, 2012
- Genetics and pharmacogenetics of the leukotriene pathwayJournal of Allergy and Clinical Immunology, 2009
- Leukotriene Signaling in Atherosclerosis and IschemiaCardiovascular Drugs and Therapy, 2008
- TNF-α downregulates the leukotriene C4synthase gene in mononuclear phagocytesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Cysteinyl leukotrienes: multi‐functional mediators in allergic rhinitisClinical & Experimental Allergy, 2006
- Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumorsNeuroscience Letters, 2004
- Targeted Gene Disruption Reveals the Role of Cysteinyl Leukotriene 1 Receptor in the Enhanced Vascular Permeability of Mice Undergoing Acute Inflammatory ResponsesJournal of Biological Chemistry, 2002
- Stimulation of human endothelial cell prostacyclin synthesis by select leukotrienes.Journal of Experimental Medicine, 1984